| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 106.61% | Needham | $2.8 → $2.5 | Maintains | Buy |
| 09/26/2023 | 230.58% | Cantor Fitzgerald | → $4 | Reiterates | Overweight → Overweight |
| 08/22/2023 | 230.58% | Cantor Fitzgerald | → $4 | Reiterates | Overweight → Overweight |
| 08/16/2023 | 230.58% | Cantor Fitzgerald | → $4 | Reiterates | Overweight → Overweight |
| 08/16/2023 | 131.4% | Needham | → $2.8 | Reiterates | Buy → Buy |
| 05/17/2023 | 230.58% | Cantor Fitzgerald | $4.5 → $4 | Maintains | Overweight |
| 05/17/2023 | 131.4% | Needham | $2.6 → $2.8 | Maintains | Buy |
| 04/21/2023 | 114.88% | Needham | → $2.6 | Reiterates | → Buy |
| 03/14/2023 | 114.88% | Needham | $3.1 → $2.6 | Maintains | Buy |
| 11/18/2022 | 189.26% | BTIG | $5 → $3.5 | Maintains | Buy |
| 11/15/2022 | 156.2% | Needham | $4.25 → $3.1 | Maintains | Buy |
| 08/16/2022 | 251.24% | Needham | $5 → $4.25 | Maintains | Buy |
| 05/12/2022 | 313.22% | Needham | $7 → $5 | Maintains | Buy |
| 03/29/2022 | 891.74% | Canaccord Genuity | $18 → $12 | Maintains | Buy |
| 03/29/2022 | 478.51% | Needham | $13 → $7 | Maintains | Buy |
| 12/27/2021 | 1222.31% | Ascendiant Capital | → $16 | Initiates Coverage On | → Buy |
| 12/15/2021 | 974.38% | Needham | $17 → $13 | Maintains | Buy |
| 11/08/2021 | 1057.02% | BTIG | → $14 | Initiates Coverage On | → Buy |
| 11/08/2021 | 1387.6% | Canaccord Genuity | → $18 | Initiates Coverage On | → Buy |
| 11/08/2021 | 1635.54% | Cantor Fitzgerald | → $21 | Initiates Coverage On | → Overweight |
| 11/08/2021 | 1304.96% | Needham | → $17 | Initiates Coverage On | → Buy |
What is the target price for Lucid Diagnostics (LUCD)?
The latest price target for Lucid Diagnostics (NASDAQ: LUCD) was reported by Needham on November 14, 2023. The analyst firm set a price target for $2.50 expecting LUCD to rise to within 12 months (a possible 106.61% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lucid Diagnostics (LUCD)?
The latest analyst rating for Lucid Diagnostics (NASDAQ: LUCD) was provided by Needham, and Lucid Diagnostics maintained their buy rating.
When is the next analyst rating going to be posted or updated for Lucid Diagnostics (LUCD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lucid Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lucid Diagnostics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
Is the Analyst Rating Lucid Diagnostics (LUCD) correct?
While ratings are subjective and will change, the latest Lucid Diagnostics (LUCD) rating was a maintained with a price target of $2.80 to $2.50. The current price Lucid Diagnostics (LUCD) is trading at is $1.21, which is out of the analyst's predicted range.